Divi's Laboratories Limited (NSE:DIVISLAB)
India
· Delayed Price · Currency is INR 6,473.50
+4.50 (0.07%)
At close: Dec 5, 2025
Divi's Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 100,290 | 93,600 | 78,450 | 77,670 | 89,598 | 69,694 | Upgrade
|
| Other Revenue | - | - | - | - | 0.9 | 0.7 | Upgrade
|
| Revenue | 100,290 | 93,600 | 78,450 | 77,670 | 89,599 | 69,695 | Upgrade
|
| Revenue Growth (YoY) | 16.43% | 19.31% | 1.00% | -13.31% | 28.56% | 29.20% | Upgrade
|
| Cost of Revenue | 39,320 | 37,250 | 33,520 | 32,740 | 31,662 | 24,771 | Upgrade
|
| Gross Profit | 60,970 | 56,350 | 44,930 | 44,930 | 57,938 | 44,924 | Upgrade
|
| Selling, General & Admin | 13,560 | 12,580 | 11,060 | 9,870 | 9,571 | 8,367 | Upgrade
|
| Other Operating Expenses | 14,910 | 14,050 | 11,780 | 11,370 | 9,526 | 7,853 | Upgrade
|
| Operating Expenses | 32,780 | 30,650 | 26,620 | 24,670 | 22,212 | 18,776 | Upgrade
|
| Operating Income | 28,190 | 25,700 | 18,310 | 20,260 | 35,726 | 26,148 | Upgrade
|
| Interest Expense | -120 | -20 | -30 | - | -3.7 | -3.9 | Upgrade
|
| Interest & Investment Income | 2,950 | 2,950 | 3,010 | 2,050 | 689.6 | 572.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,220 | 480 | 300 | 1,300 | 405.8 | -43.8 | Upgrade
|
| Other Non Operating Income (Expenses) | 100 | 40 | 30 | 40 | 38.1 | 21.2 | Upgrade
|
| EBT Excluding Unusual Items | 32,340 | 29,150 | 21,620 | 23,650 | 36,856 | 26,694 | Upgrade
|
| Gain (Loss) on Sale of Investments | 50 | 50 | 50 | 50 | - | 26.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | -40 | -40 | -40 | -10 | -20.5 | -59.6 | Upgrade
|
| Pretax Income | 32,350 | 29,160 | 21,630 | 23,690 | 36,835 | 26,660 | Upgrade
|
| Income Tax Expense | 7,500 | 7,250 | 5,630 | 5,450 | 7,231 | 6,818 | Upgrade
|
| Net Income | 24,850 | 21,910 | 16,000 | 18,240 | 29,605 | 19,843 | Upgrade
|
| Net Income to Common | 24,850 | 21,910 | 16,000 | 18,240 | 29,605 | 19,843 | Upgrade
|
| Net Income Growth | 35.35% | 36.94% | -12.28% | -38.39% | 49.19% | 44.15% | Upgrade
|
| Shares Outstanding (Basic) | 266 | 265 | 265 | 265 | 265 | 265 | Upgrade
|
| Shares Outstanding (Diluted) | 266 | 265 | 265 | 265 | 265 | 265 | Upgrade
|
| EPS (Basic) | 93.60 | 82.53 | 60.27 | 68.71 | 111.52 | 74.75 | Upgrade
|
| EPS (Diluted) | 93.59 | 82.53 | 60.27 | 68.69 | 111.52 | 74.75 | Upgrade
|
| EPS Growth | 35.35% | 36.93% | -12.26% | -38.41% | 49.19% | 44.16% | Upgrade
|
| Free Cash Flow | 540 | 2,150 | 2,580 | 19,860 | 11,986 | 10,367 | Upgrade
|
| Free Cash Flow Per Share | 2.03 | 8.10 | 9.72 | 74.81 | 45.15 | 39.05 | Upgrade
|
| Dividend Per Share | - | 30.000 | 30.000 | 30.000 | 30.000 | 20.000 | Upgrade
|
| Dividend Growth | - | - | - | - | 50.00% | 25.00% | Upgrade
|
| Gross Margin | 60.79% | 60.20% | 57.27% | 57.85% | 64.66% | 64.46% | Upgrade
|
| Operating Margin | 28.11% | 27.46% | 23.34% | 26.09% | 39.87% | 37.52% | Upgrade
|
| Profit Margin | 24.78% | 23.41% | 20.39% | 23.48% | 33.04% | 28.47% | Upgrade
|
| Free Cash Flow Margin | 0.54% | 2.30% | 3.29% | 25.57% | 13.38% | 14.88% | Upgrade
|
| EBITDA | 32,460 | 29,680 | 22,050 | 23,640 | 38,801 | 28,666 | Upgrade
|
| EBITDA Margin | 32.37% | 31.71% | 28.11% | 30.44% | 43.30% | 41.13% | Upgrade
|
| D&A For EBITDA | 4,270 | 3,980 | 3,740 | 3,380 | 3,075 | 2,518 | Upgrade
|
| EBIT | 28,190 | 25,700 | 18,310 | 20,260 | 35,726 | 26,148 | Upgrade
|
| EBIT Margin | 28.11% | 27.46% | 23.34% | 26.09% | 39.87% | 37.52% | Upgrade
|
| Effective Tax Rate | 23.18% | 24.86% | 26.03% | 23.00% | 19.63% | 25.57% | Upgrade
|
| Revenue as Reported | 104,610 | 97,120 | 81,840 | 81,120 | 90,737 | 70,320 | Upgrade
|
| Advertising Expenses | - | - | - | - | 1.6 | 0.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.